AMVUTTRA

VUTRISIRAN · Alnylam Pharmaceuticals, Inc.

Drug timelines are a Plus or Pro feature.

8 regulatory and trial events tracked for AMVUTTRA, covering 2022-06-13 to 2026-02-20. Get the full timeline:

Most recent: Clinical Trial Update: A Study to Evaluate Vutrisiran in Patients With Transthyretin Amyloidosis With Cardiomyopathy [Phase 3]